Merrimack Pharmaceuticals Stock Price, News & Analysis (NASDAQ:MACK)

$11.29 +0.08 (+0.71 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$11.29
Today's Range$10.95 - $11.35
52-Week Range$9.68 - $39.90
Volume77,561 shs
Average Volume134,028 shs
Market Capitalization$150.53 million
P/E Ratio-1.55
Dividend YieldN/A
Beta1.73

About Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:MACK
CUSIP59032810
Phone+1-617-4411000

Debt

Debt-to-Equity Ratio0.45%
Current Ratio3.35%
Quick Ratio3.35%

Price-To-Earnings

Trailing P/E Ratio-1.54869684499314
Forward P/E Ratio-3.58
P/E GrowthN/A

Sales & Book Value

Annual Sales$144.27 million
Price / Sales1.04
Cash FlowN/A
Price / CashN/A
Book Value($19.27) per share
Price / Book-0.59

Profitability

Trailing EPS($7.29)
Net Income$-151,740,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-68.02%

Miscellaneous

Employees294
Outstanding Shares13,340,000

Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals declared an annual dividend on Friday, April 7th. Investors of record on Wednesday, May 17th will be paid a dividend of $10.60 per share on Friday, May 26th. The ex-dividend date of this dividend is Tuesday, May 30th. View Merrimack Pharmaceuticals' Dividend History.

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Merrimack Pharmaceuticals shares reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) posted its earnings results on Thursday, August, 4th. The biopharmaceutical company reported ($4.00) EPS for the quarter, missing the Zacks' consensus estimate of ($3.30) by $0.70. The biopharmaceutical company earned $33.70 million during the quarter, compared to the consensus estimate of $33.35 million. Merrimack Pharmaceuticals's revenue for the quarter was up 58.3% compared to the same quarter last year. During the same period last year, the business earned ($3.30) EPS. View Merrimack Pharmaceuticals' Earnings History.

When will Merrimack Pharmaceuticals make its next earnings announcement?

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Merrimack Pharmaceuticals.

Where is Merrimack Pharmaceuticals' stock going? Where will Merrimack Pharmaceuticals' stock price be in 2018?

2 Wall Street analysts have issued 12 month target prices for Merrimack Pharmaceuticals' stock. Their forecasts range from $15.00 to $15.00. On average, they expect Merrimack Pharmaceuticals' stock price to reach $15.00 in the next year. View Analyst Ratings for Merrimack Pharmaceuticals.

Who are some of Merrimack Pharmaceuticals' key competitors?

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the folowing people:

  • Gary L. Crocker, Chairman of the Board (Age 64)
  • Richard Peters M.D. Ph.D., President, Chief Executive Officer, Director (Age 54)
  • Jean M. Franchi CPA, Chief Financial Officer,Principal Financial Officer, Principal Accounting Officer, Treasurer (Age 50)
  • John L. Green, Controller (Age 37)
  • Ellen K. Forest, Head of Human Resources
  • Sergio L. Santillana, Chief Medical Officer
  • George Demetri M.D., Director
  • Ulrik B. Nielsen Ph.D., Director (Age 44)
  • John M. Dineen, Independent Director (Age 52)
  • Vivian S. Lee, Independent Director (Age 50)

Who owns Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.09%), TIAA CREF Investment Management LLC (4.13%), Franklin Resources Inc. (2.77%), Millennium Management LLC (1.53%), Deutsche Bank AG (1.08%) and Geode Capital Management LLC (0.81%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond, Michael E Porter, Ulrik B Nielsen, Vivian S Lee and William M Mcclements. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

Who sold Merrimack Pharmaceuticals stock? Who is selling Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Franklin Resources Inc., Deutsche Bank AG, Teachers Advisors LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Merrimack Pharmaceuticals company stock in the last year include Daryl C Drummond and Ulrik B Nielsen. View Insider Buying and Selling for Merrimack Pharmaceuticals.

Who bought Merrimack Pharmaceuticals stock? Who is buying Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Yakira Capital Management Inc., Bogle Investment Management L P DE, Paloma Partners Management Co, Wittenberg Investment Management Inc., Stonebridge Capital Management Inc., Macquarie Group Ltd. and Virtu Financial LLC. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Michael E Porter, Vivian S Lee and William M Mcclements. View Insider Buying and Selling for Merrimack Pharmaceuticals.

How do I buy Merrimack Pharmaceuticals stock?

Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $11.29.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $150.53 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $-151,740,000.00 in net income (profit) each year or ($7.29) on an earnings per share basis. Merrimack Pharmaceuticals employs 294 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is 1 Kendall Sq Ste B7201, CAMBRIDGE, MA 02139-1670, United States. The biopharmaceutical company can be reached via phone at +1-617-4411000 or via email at [email protected]


MarketBeat Community Rating for Merrimack Pharmaceuticals (MACK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  248 (Vote Outperform)
Underperform Votes:  183 (Vote Underperform)
Total Votes:  431
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Merrimack Pharmaceuticals (NASDAQ:MACK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $15.00$15.00$15.00$60.00
Price Target Upside: 11.52% upside11.52% upside11.52% upside1,639.13% upside

Merrimack Pharmaceuticals (NASDAQ:MACK) Consensus Price Target History

Price Target History for Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals (NASDAQ:MACK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/13/2017Robert W. BairdReiterated RatingHold$15.00N/AView Rating Details
5/19/2017CowenReiterated RatingMarket PerformLowView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHold$70.00N/AView Rating Details
11/10/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$160.00 -> $130.00N/AView Rating Details
5/20/2016MizuhoReiterated RatingBuy$130.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Merrimack Pharmaceuticals (NASDAQ:MACK) Earnings History and Estimates Chart

Earnings by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals (NASDAQ MACK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.28)N/AView Earnings Details
11/8/2017Q3 2017($1.88)($0.40)ViewN/AView Earnings Details
8/9/2017Q2 2017($1.37)($2.18)$18.00 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.70)($2.20)$32.16 millionViewN/AView Earnings Details
3/1/2017Q416($2.10)($2.50)$50.44 million$61.20 millionViewListenView Earnings Details
11/9/2016Q316($2.70)($2.30)$41.00 million$28.07 millionViewListenView Earnings Details
8/4/2016Q216($3.30)($4.00)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($3.80)($3.30)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($4.10)($4.10)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($4.00)($3.80)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($3.10)($2.10)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015Q1 2015($3.00)($3.20)$14.50 million$14.84 millionViewN/AView Earnings Details
2/26/2015Q4($2.30)($0.90)$25.13 million$33.91 millionViewN/AView Earnings Details
11/10/2014Q3 2014($1.20)($2.70)$61.50 million$28.00 millionViewN/AView Earnings Details
8/11/2014Q2 2014($3.20)($1.70)$10.83 million$27.82 millionViewN/AView Earnings Details
5/1/2014Q114($3.10)($2.70)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($2.90)($3.30)$11.61 million$7.82 millionViewN/AView Earnings Details
11/7/2013($3.40)($3.90)$15.86 million$6.86 millionViewN/AView Earnings Details
8/8/2013Q2 2013($2.80)($3.10)$13.68 million$18.45 millionViewN/AView Earnings Details
5/13/2013Q1 2013($2.80)($2.90)$11.68 million$14.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($2.60)($17.60)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($18.10)$8.60 million$11.30 millionViewN/AView Earnings Details
8/10/2012Q2 2012($2.70)($2.21)ViewN/AView Earnings Details
5/15/2012Q1 2012($2.30)($21.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Merrimack Pharmaceuticals (NASDAQ:MACK) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.15 EPS
Next Year EPS Consensus Estimate: $-5.44 EPS

Dividends

Merrimack Pharmaceuticals (NASDAQ:MACK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/7/2017Annual$10.605/30/20175/17/20175/26/2017
(Data available from 1/1/2013 forward)

Insider Trades

Merrimack Pharmaceuticals (NASDAQ MACK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.53%
Institutional Ownership Percentage: 52.32%
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Institutional Ownership by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals (NASDAQ MACK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2017Ulrik B NielsenDirectorSell7,896$14.23$112,360.0822,781View SEC Filing  
9/14/2017Ulrik B NielsenDirectorSell100$14.20$1,420.0022,781View SEC Filing  
9/13/2017Ulrik B NielsenDirectorSell21,556$14.40$310,406.4037,437View SEC Filing  
9/11/2017Ulrik B NielsenDirectorSell14,756$14.46$213,371.7637,437View SEC Filing  
5/12/2017Daryl C DrummondInsiderSell4,097$3.72$15,240.84View SEC Filing  
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00115,657View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00754,448View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00749,448View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00744,448View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00724,448View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00709,448View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.0065,000View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.0014,072View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.0021,385View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.0021,385View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.0021,385View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.0021,385View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.0021,385View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.0021,385View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00699,448View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.0021,385View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.002,808,571View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.002,804,571View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00535,865View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00520,865View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.002,783,271View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00485,865View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00946,069View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00470,865View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.0013,000View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00445,865View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.0051,500View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00989,644View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00976,994View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.009,000View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00392,543View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Merrimack Pharmaceuticals (NASDAQ MACK) News Headlines

Source:
DateHeadline
Whats in the Cards for Merrimack (MACK) in Q4 Earnings?What's in the Cards for Merrimack (MACK) in Q4 Earnings?
www.msn.com - February 23 at 5:58 PM
What's in the Cards for Merrimack (MACK) in Q4 Earnings?What's in the Cards for Merrimack (MACK) in Q4 Earnings?
finance.yahoo.com - February 23 at 5:58 PM
Zacks: Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) to Post -$0.28 EPSZacks: Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) to Post -$0.28 EPS
www.americanbankingnews.com - February 21 at 7:10 PM
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology - PR Newswire (press release)Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology - PR Newswire (press release)
www.prnewswire.com - February 20 at 8:17 AM
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision OncologyMerrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
finance.yahoo.com - February 20 at 8:17 AM
Merrimack Pharmaceuticals (MACK) to Release Earnings on TuesdayMerrimack Pharmaceuticals (MACK) to Release Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:12 AM
Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare ConferenceMerrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 15 at 9:19 AM
Merrimack Pharmaceuticals Inc (MACK) Expected to Post Quarterly Sales of $33.00 MillionMerrimack Pharmaceuticals Inc (MACK) Expected to Post Quarterly Sales of $33.00 Million
www.americanbankingnews.com - February 6 at 3:52 AM
Zacks: Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) Will Post Earnings of -$0.28 Per ShareZacks: Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) Will Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - February 4 at 7:08 PM
Need for radiation sickness drug a sign of scary timesNeed for radiation sickness drug a sign of scary times
www.msn.com - February 1 at 9:40 AM
Contrasting Prana Biotechnology (PRAN) & Merrimack Pharmaceuticals (MACK)Contrasting Prana Biotechnology (PRAN) & Merrimack Pharmaceuticals (MACK)
www.americanbankingnews.com - January 27 at 3:32 AM
-$0.28 Earnings Per Share Expected for Merrimack Pharmaceuticals Inc (MACK) This Quarter-$0.28 Earnings Per Share Expected for Merrimack Pharmaceuticals Inc (MACK) This Quarter
www.americanbankingnews.com - January 18 at 9:34 PM
Merrimack to Present at the 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)Merrimack to Present at the 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - January 5 at 4:59 PM
Merrimack to Present at the 36th Annual J.P. Morgan Healthcare ConferenceMerrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:36 AM
Merrimack Pharmaceuticals Inc (MACK) Expected to Post Earnings of -$0.28 Per ShareMerrimack Pharmaceuticals Inc (MACK) Expected to Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - January 2 at 3:30 AM
Reviewing Merrimack Pharmaceuticals (MACK) & Its PeersReviewing Merrimack Pharmaceuticals (MACK) & Its Peers
www.americanbankingnews.com - December 18 at 3:28 AM
Head to Head Contrast: Merrimack Pharmaceuticals (MACK) versus Its PeersHead to Head Contrast: Merrimack Pharmaceuticals (MACK) versus Its Peers
www.americanbankingnews.com - December 17 at 1:28 PM
Merrimack Pharmaceuticals, Inc. (MACK) Expected to Post Earnings of -$0.28 Per ShareMerrimack Pharmaceuticals, Inc. (MACK) Expected to Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - December 16 at 11:28 AM
Merrimack Pharmaceuticals (MACK) versus Its Competitors Financial ContrastMerrimack Pharmaceuticals (MACK) versus Its Competitors Financial Contrast
www.americanbankingnews.com - December 15 at 9:30 PM
BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 MlnBRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln
www.reuters.com - December 15 at 5:46 PM
Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound?Merrimack (MACK) Down 7.8% Since Earnings Report: Can It Rebound?
finance.yahoo.com - December 11 at 10:22 AM
Merrimack Pharmaceuticals (MACK) & Its Peers Financial SurveyMerrimack Pharmaceuticals (MACK) & Its Peers Financial Survey
www.americanbankingnews.com - December 10 at 1:36 PM
$33.00 Million in Sales Expected for Merrimack Pharmaceuticals, Inc. (MACK) This Quarter$33.00 Million in Sales Expected for Merrimack Pharmaceuticals, Inc. (MACK) This Quarter
www.americanbankingnews.com - November 30 at 8:16 PM
Form 8-K MERRIMACK PHARMACEUTICAL For: Nov 26 - StreetInsider.comForm 8-K MERRIMACK PHARMACEUTICAL For: Nov 26 - StreetInsider.com
www.streetinsider.com - November 30 at 5:08 PM
Merrimack Announces Appointment of George Demetri, M.D., to ... - PR Newswire (press release)Merrimack Announces Appointment of George Demetri, M.D., to ... - PR Newswire (press release)
www.prnewswire.com - November 30 at 5:08 PM
Merrimack Announces Appointment of George Demetri, M.D., to Board of DirectorsMerrimack Announces Appointment of George Demetri, M.D., to Board of Directors
finance.yahoo.com - November 30 at 10:07 AM
Critical Contrast: Merrimack Pharmaceuticals (MACK) vs. Charles River Laboratories International (CRL)Critical Contrast: Merrimack Pharmaceuticals (MACK) vs. Charles River Laboratories International (CRL)
www.americanbankingnews.com - November 23 at 7:28 PM
Contrasting Merrimack Pharmaceuticals (MACK) and The CompetitionContrasting Merrimack Pharmaceuticals (MACK) and The Competition
www.americanbankingnews.com - November 22 at 11:31 AM
With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Inc’s (MACK) Management Done A Good Job?With An ROE Of 175.74%, Has Merrimack Pharmaceuticals Inc’s (MACK) Management Done A Good Job?
finance.yahoo.com - November 21 at 3:26 AM
Merrimack Pharmaceuticals, Inc. (MACK) Expected to Post Quarterly Sales of $24.00 MillionMerrimack Pharmaceuticals, Inc. (MACK) Expected to Post Quarterly Sales of $24.00 Million
www.americanbankingnews.com - November 11 at 6:40 AM
 Analysts Anticipate Merrimack Pharmaceuticals, Inc. (MACK) Will Announce Earnings of -$1.30 Per Share Analysts Anticipate Merrimack Pharmaceuticals, Inc. (MACK) Will Announce Earnings of -$1.30 Per Share
www.americanbankingnews.com - November 9 at 1:44 PM
Edited Transcript of MACK earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of MACK earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 8 at 9:39 PM
Merrimack Reports Third Quarter 2017 Financial Results - PR Newswire (press release)Merrimack Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - November 8 at 4:38 PM
Merrimack Pharmaceuticals, Inc. to Host Earnings CallMerrimack Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 4:38 PM
Merrimack Reports Third Quarter 2017 Financial ResultsMerrimack Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 4:38 PM
Merrimack's (MACK) Reports Narrower-than-Expected Q3 LossMerrimack's (MACK) Reports Narrower-than-Expected Q3 Loss
finance.yahoo.com - November 8 at 4:38 PM
Merrimack beats 3Q profit forecastsMerrimack beats 3Q profit forecasts
finance.yahoo.com - November 8 at 4:38 PM
What's in the Cards for Merrimack (MACK) in Q3 Earnings?What's in the Cards for Merrimack (MACK) in Q3 Earnings?
finance.yahoo.com - November 7 at 6:37 AM
Merrimack Announces Timing of Third Quarter 2017 Investor Conference CallMerrimack Announces Timing of Third Quarter 2017 Investor Conference Call
finance.yahoo.com - November 2 at 6:12 AM
Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call - PR Newswire (press release)Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call - PR Newswire (press release)
www.prnewswire.com - November 2 at 6:12 AM
Merrimack Pharmaceuticals, Inc. (MACK) Set to Announce Earnings on TuesdayMerrimack Pharmaceuticals, Inc. (MACK) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:36 AM
Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung CancerMerrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer
finance.yahoo.com - October 31 at 3:14 AM
Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121Merrimack Pharmaceuticals Inc (MACK) Granted FDA Orphan-Drug Designation for MM-121
finance.yahoo.com - October 31 at 3:14 AM
Have Investors Already Priced In Merrimack Pharmaceuticals Inc’s (MACK) Growth?Have Investors Already Priced In Merrimack Pharmaceuticals Inc’s (MACK) Growth?
finance.yahoo.com - October 29 at 6:35 AM
Merrimack Pharmaceuticals, Inc. (MACK) Receives Consensus Rating of "Hold" from AnalystsMerrimack Pharmaceuticals, Inc. (MACK) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 26 at 1:56 PM
Merrimack Pharmaceuticals (MACK) Hold Rating Reaffirmed at Robert W. BairdMerrimack Pharmaceuticals' (MACK) Hold Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - October 14 at 10:12 PM
Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020 - PR Newswire (press release)Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020 - PR Newswire (press release)
www.prnewswire.com - October 14 at 2:26 AM
Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020
finance.yahoo.com - October 14 at 2:26 AM
Merrimack Pharma (MACK) Settles Convertible Note LitigationMerrimack Pharma (MACK) Settles Convertible Note Litigation
www.streetinsider.com - October 12 at 6:44 AM
Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio?Merrimack Pharmaceuticals Inc (MACK): How Does It Impact Your Portfolio?
finance.yahoo.com - October 11 at 1:09 AM

SEC Filings

Merrimack Pharmaceuticals (NASDAQ:MACK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Merrimack Pharmaceuticals (NASDAQ:MACK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Merrimack Pharmaceuticals (NASDAQ MACK) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.